title: Trastuzumab in metastatic breast cancer after complete remission: How long is enough?
authors.affiliation: Medical Oncology Department, Baskent University, 5th Street Bahcelievler, Ankara, Turkey, oguzarzu@yahoo.com.
authors.forename: Arzu
authors.initials: A
authors.lastname: Oguz
authors.forename: Samed
authors.initials: S
authors.lastname: Rahatli
authors.forename: Ozden
authors.initials: O
authors.lastname: Altundag
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D000068878:Trastuzumab / Q000627:therapeutic use*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human